ClinicalTrials.gg
Not yet recruitingNCT07942220POP-SVUpdated Nov 17, 2026

Post-ejaculatory Optimization and Physiology of the Seminal Vesicles: A Prospective Paired MRI/CT, Contouring and Dosimetric Pilot Study

An interventional study of 72-hour ejaculation abstinence, followed by ejaculation in Prostate Cancer, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Prostatic Neoplasms by University Health Network, Toronto — 23 open to participants now, 29 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.

Planned enrollment
67th of 86
18 · median 44
Started
2026
with 4 others
No phase
44 of 102
13 open now
Primary completion
2027-11
later than 9 of 28 live
Registered
102nd of 102
by date

Among the 102 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 67th largest by planned enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2026, is one of 44 with no phase, reaches primary completion later than 9 of the 28 other live ones, and was the 102nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

23 of the 102 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 23 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Prostatic Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

The purpose of this study is to measure how ejaculation changes the size, shape and position of the seminal vesicles on MRI and CT scans, and whether these changes could affect radiation treatment planning.

Participants will be aksed to not ejaculate for at least 3 days prior to the visit. On the day of the visit, participants will complete standard of care MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans. These scans are already used in medical care but would not normally be done more than once before receiving radiation treatment. The second set of scans CT and MRI are part of the study will occur on the same day, 30-60 minutes after you ejaculate into a provided container.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. Prostate cancer planned for curative-intent radiotherapy.
  3. Patient undergoing SOC prostate MR simulation for radiotherapy planning.
  4. Has successfully ejaculated within the 30 days preceding consent.
  5. Able and willing to abstain from ejaculation for at least 72 hours prior to completion of the baseline SOC MR and CT simulation imaging.
  6. Able and willing to undergo masturbation-induced ejaculation for study purposes and collect the ejaculate into the provided specimen container.

Exclusion criteria

Exclusion Criteria:

  1. Prior bilateral seminal vesiculectomy or other surgery that precludes meaningful seminal vesicle assessment.
  2. Anatomical distortion or disease extent judged by the investigator to prevent reliable seminal vesicle contouring.
  3. Previous TURP (transurethral resection of the prostate) or any other anatomic condition that may cause retrograde ejaculation.
  4. Ongoing treatment at time of study procedures with medications known to cause retrograde ejaculation such as alpha-1 blockers (e.g. tamsulosin).
  5. Active genitourinary infection or other condition in which ejaculation would be medically inappropriate or unduly uncomfortable.
  6. Inability to comply with study procedures.
  7. Any circumstance in which the investigator believes participation would interfere with timely clinical care.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Pre-Ejaculation Imaging and Post-Ejaculation Imaging

    Each participant will serve as their own control. Participants with prostate cancer undergoing standard-of-care (SOC) MR and CT simulation for radiotherapy planning will be approached. Following a standardized period of ejaculatory abstinence (i.e., \> 72hrs), the patient's SOC MR simulation and CT simulation will provide the baseline pre-ejaculation imaging datasets. After completion of the baseline simulation imaging, participants will undergo masturbation-induced ejaculation in a private setting, collect the ejaculate into a pre-weighed specimen container, and undergo repeat research imaging beginning approximately 30-60 minutes following ejaculation.

    Behavioral: 72-hour ejaculation abstinence, followed by ejaculation

Interventions

  • Behavioral72-hour ejaculation abstinence, followed by ejaculation

    Before baseline imaging, participants will be asked to not ejaculate for at least 72 hours. After baseline imaging, participants will undergo masturbation-induced ejaculation, which will be followed by repeat research imaging.

06

What researchers measure

Primary outcomes

  1. Change in Total Seminal Vesicle Volume

    Paired absolute and relative change in total seminal vesicle volume on MR from pre-ejaculation to post-ejaculation

    Time frame: From baseline imaging to repeat research imaging (1 day)

Secondary outcomes

  1. Change in Right, Left, Combined and Proximal Seminal Vesicle Volume

    Right/left and proximal seminal vesicle volume change from pre-ejaculation to post-ejaculation

    Time frame: From baseline imaging to repeat research imaging (1 day)

  2. Association of Ejaculation and Changes in Seminal Vesicle Shape and Position

    Dice similarity coefficient, surface-distance and centroid-displacement metrics to measure contour overlap, surface distance, centroid displacement and orientation/angulation

    Time frame: From baseline imaging to repeat research imaging (1 day)

  3. Correlation between Ejaculate Volume with absolute and relative seminal vesicle volume change and seminal vesicle emptying fraction

    Ejaculate mass collected from masturbation-induced ejaculation will be weighed in grams and used as an estimate of ejaculate volume in milliliters. Correlation will be assessed using Pearson or Spearman correlation, with simple linear regression used descriptively.

    Time frame: From baseline imaging to repeat research imaging (1 day)

  4. Impact of ejaculation and imaging condition on inter-observer and intra-observer seminal vesicle contouring variability

    Intra- and inter-observer contouring variability on MR alone, CT alone and CT with co-registered MRI available for review

    Time frame: From baseline imaging to repeat research imaging (1 day)

  5. Estimate the dosimetric impact of post-ejaculatory seminal vesicle changes

    Changes in selected target-coverage and organ-at-risk dosimetric metrics

    Time frame: From baseline imaging to repeat research imaging (1 day)

  6. Compare ejaculation-associated seminal vesicle volumetric and geometric changes and characterize agreement between modalities

    Paired CT-based volumetric/geometric change and MR-CT agreement

    Time frame: From baseline imaging to repeat research imaging (1 day)

  7. Determine whether access to co-registered MR during CT-based contouring improves seminal vesicle delineation reproducibility and preserves detection of ejaculation-associated anatomical change compared with CT alone

    Incremental effect of MR fusion on CT-based contouring reproducibility

    Time frame: From baseline imaging to repeat research imaging (1 day)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 17, 2026
StartEst.
Nov 23, 2026
Primary completionEst.
Nov 23, 2027
CompletionEst.
Nov 23, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942220
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 23, 2026 (estimated)
Primary completion
Nov 23, 2027 (estimated)
Completion
Nov 23, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Alejandro Berlin, MD
Contact
alejandro.berlin@uhn.ca
416-946-4501 ext. 5813

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion